Tenax Therapeutics, Inc. (NASDAQ:TENX) registered a -9.72% decrease, still its new closing price is 61.16% up from the company’s 1 year high of 2.94.It posted -15.22% losses in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 2 stock analysts following this company have an average price target at $9.25, with individual PT in the $8.00-$10.50 range. The shares moved at $1.95, implying that brokerage firms see shares losing about -25.86% in twelve months time.
Tenax Therapeutics, Inc. (TENX) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 0.00% rise year to date. A Director at Tenax Therapeutics, Inc. (TENX) acquired shares in a transaction closed on Wednesday November 23, 2016. PROEHL GERALD T bought 29,882 shares in the company at $1.67 each and collected $49,001 in proceeds. PROEHL GERALD T now owns 29,882 shares in the company after this transaction. A Director in the company, Mitchum James P., disclosed a transaction on Wednesday February 03, 2016 that ended up paying $50,001 from the purchase of 19,000 shares at $2.66 per share.
Tenax Therapeutics, Inc. (NASDAQ:TENX) Upcoming Results on Tap
Tenax Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.12 in that period. Sales during the quarter are predicted to arrive at $0.
Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.15. The mean forecast was for $0 and $-0.17 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.17/share.
Tenax Therapeutics, Inc. (TENX) Brokerage Update
Over the last six months and over the last three months, the shares of Tenax Therapeutics, Inc. (TENX), have changed -20.73% and 12.72%, respectively.